ArticleTranslational lung cancer research2019

Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer.

Yunpeng Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.